PMID- 14991893
OWN - NLM
STAT- MEDLINE
DCOM- 20040416
LR  - 20141120
IS  - 0022-3417 (Print)
IS  - 0022-3417 (Linking)
VI  - 202
IP  - 3
DP  - 2004 Mar
TI  - Comparative multi-methodological measurement of ERBB2 status in breast cancer.
PG  - 286-98
AB  - The ERBB2 transmembrane tyrosine kinase receptor is both a prognostic marker and 
      a therapeutic target in breast cancer. Accurate determination of ERBB2 status is 
      a prerequisite for the establishment of prognostic significance and for the 
      selection of ERBB2-overexpressing breast tumours for specific treatment. 
      Unfortunately, there is no complete agreement on how this determination should be 
      performed. This study has compared four methods of assessment of ERBB2 status. 
      Two global, extraction-based methods using real-time quantitative PCR on DNA 
      (Q-PCR) or RNA (RQ-PCR) and two non-global, tissue-based methods, ie fluorescence 
      in situ hybridization (FISH) and immunohistochemistry (IHC), were used. The 94 
      breast cancers tested were enriched in cases scoring 2+ using the IHC scoring 
      system currently in use and for which the actual ERBB2 status remains ill 
      defined. To determine the best parameters and reagents for assessment, two 
      protocols for FISH and five anti-ERBB2 antibodies were used, and both FISH and 
      IHC were carried out on the same tissue microarrays (TMAs). It is shown that the 
      combination of the two tissue-based methods gives the best results. The use of 
      either PCR-based method did not improve the results significantly. A new combined 
      IHC score based on the association of two selected anti-ERBB2 antibodies 
      (HercepTest trade mark and TAB250) and a dual scale for improved assessment of 
      ERBB2 protein expression, particularly in 2+ cases, are proposed.
CI  - Copyright 2004 Pathological Society of Great Britain and Ireland. Published by 
      John Wiley & Sons, Ltd.
FAU - Ginestier, Christophe
AU  - Ginestier C
AD  - Departement d'Oncologie Moleculaire, Institut Paoli-Calmettes et U119 Inserm, 
      IFR57, Marseille, France.
FAU - Charafe-Jauffret, Emmanuelle
AU  - Charafe-Jauffret E
FAU - Penault-Llorca, Frederique
AU  - Penault-Llorca F
FAU - Geneix, Jeannine
AU  - Geneix J
FAU - Adelaide, Jose
AU  - Adelaide J
FAU - Chaffanet, Max
AU  - Chaffanet M
FAU - Mozziconacci, Marie-Joelle
AU  - Mozziconacci MJ
FAU - Hassoun, Jacques
AU  - Hassoun J
FAU - Viens, Patrice
AU  - Viens P
FAU - Birnbaum, Daniel
AU  - Birnbaum D
FAU - Jacquemier, Jocelyne
AU  - Jacquemier J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - J Pathol
JT  - The Journal of pathology
JID - 0204634
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*chemistry
MH  - Cell Line, Tumor
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry/methods
MH  - In Situ Hybridization, Fluorescence
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Receptor, ErbB-2/*analysis
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sensitivity and Specificity
EDAT- 2004/03/03 05:00
MHDA- 2004/04/17 05:00
CRDT- 2004/03/03 05:00
PHST- 2004/03/03 05:00 [pubmed]
PHST- 2004/04/17 05:00 [medline]
PHST- 2004/03/03 05:00 [entrez]
AID - 10.1002/path.1523 [doi]
PST - ppublish
SO  - J Pathol. 2004 Mar;202(3):286-98. doi: 10.1002/path.1523.